Projects

Carmine SELLERI Projects

4 Funded projects
Filter
In this study, we aim at investigating the impact of ruxolitinib on marrow fibrosis in MPNs using a well-established 3D in vitro model of BM niche mimicking cell-to-cell contacts and paracrine pathways intercurrent between stromal cells and BMMCs in normal and pathological hematopoiesis.Specific aims: 1. Establishment of a 3D in vitro co-culture model of myelofibrosis.2. Ruxolitinib effects on
DepartmentDipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED
Principal InvestigatorSELLERI Carmine (Project Coordinator)
FundingUniversity funds
Cost3.505,26 euro
Project duration31 July 2023 - 31 July 2026
Detail
Based on findings showing the involvement of proinflammatory low-density granulocytes (LDGs) in activation of type 1 helper responses, and on the predominant role of cytotoxic T cells and type I immune responses in myelodysplastic syndromes (MDS), we hypothesize that LDGs and other immunoregulatory molecules might play an important role in MDS pathophysiology. Specific aims are to: 1) detect and q
DepartmentDipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED
Principal InvestigatorSELLERI Carmine (Project Coordinator)
FundingUniversity funds
FundersUniversità  degli Studi di SALERNO
Cost3.455,31 euro
Project duration25 July 2022 - 25 July 2025
Detail
Studio di marcatori di risposta al trattamento in pazienti con neoplasie ematologiche
DepartmentDipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED
Principal InvestigatorSELLERI Carmine (Project Coordinator)
FundingFinanziamenti da privati italiani
FundersABBVIE S.R.L.
Cost38.098,00 euro
Project duration7 February 2022 - 31 December 2024
Detail
The discovery of checkpoint inhibitors and engineered T cells has opened a new era in cancer immunotherapy and has changed clinical outcomes of several tumors. T cells expressing chimeric antigen receptors (CARs) are directed against specific tumor-related antigens. To date, only two CD19-specific CAR-T cells have been approved for B-cell acute lymphoblastic leukemia and diffuse large B cell lymph
DepartmentDipartimento di Medicina, Chirurgia e Odontoiatria “Scuola Medica Salernitana”/DIPMED
Principal InvestigatorSELLERI Carmine (Project Coordinator)
FundingUniversity funds
FundersUniversità  degli Studi di SALERNO
Cost1.947,43 euro
Project duration22 November 2021 - 22 November 2024
Detail

  Data source U-GOV dal 1 Gennaio 2013